(EMAILWIRE.COM, November 19, 2018 ) Browse 87 market data tables and 41 figures spread through 148 pages and in-depth TOC on "Topical Drug Delivery Market"
https://www.marketsandmarkets.com/Market-Reports/topical-drug-delivery-market-124871717.html
Early buyers will receive 10% customization on this report.

Galderma S.A. (Switzerland), GlaxoSmithKline plc (U.K.), Valeant Pharmaceuticals International, Inc. (Canada), Crescita Therapeutics Inc. (Canada), Medpharm (U.K.), 3M (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), Janssen Global Services, LLC (U.S.), and Cipla (India) are the prominent players operating in the topical drug delivery market.

GlaxoSmithKline (GSK) plc is the leading player in this market. The company offers products for various dermatological conditions, such as acne, dermatoses, fungal infections, atopic dermatitis, psoriasis, superficial skin infections, and non-melanoma skin cancer. The company primarily focuses on inorganic growth strategies to strengthen its position in the market.

Download the PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124871717

For instance, in 2009, GSK acquired Stiefel Laboratories Inc. (U.S.), a dermatological pharmaceutical company, for USD 2.9 billion. Through this acquisition, GSK combined its existing dermatological products with Stiefel’s products.

Novartis AG is the next leading player in the topical drug delivery market. The company manufactures healthcare and pharmaceutical products. It operates in three segments, namely, Pharmaceuticals, Alcon (Eye Care), and Sandoz (Generics). The company has a broad range of access-to-medicine programs which include drug donations, selling at cost, social business initiatives, and patient assistance programs.

In order to maintain its position, the company invests in R&D activities which help it to develop and launch new and advanced products. In 2015, the company invested 18.1% of its total revenue on R&D activities, as compared to 17.4% in 2014. Novartis also focuses on acquisitions to sustain its strong presence in the market. For instance, in December 2016, Novartis acquired Ziarco Group Limited (U.K.), a privately held company focused on the development of novel treatments in dermatology. This acquisition strengthened Novartis’ dermatology portfolio and pipeline.

The overall growth strategies mapped from January 2013 to June 2017 include partnerships, agreements, collaborations, alliances, product launches and approvals, acquisitions, and expansions. Among these, product launches & product approvals and expansions were the key strategies adopted by industry players to achieve growth. Galderma S.A. (Switzerland), Valeant Pharmaceuticals International, Inc. (Canada), and Janssen Global Services LLC (U.S.) were some of the key players that adopted these strategies.

Get the Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=124871717

For instance, in December 2016, Galderma S.A received approval from the U.S. Food and Drug Administration (FDA) to market Restylane Refyne and Restylane Defyne. Similarly, in September 2016, Crescita Therapeutics Inc. received approval for its Pliaglis topical anesthetic cream for commercial sale in Mexico. In November 2014, Valeant Pharmaceuticals received an approval from the U.S. Food and Drug Administration for ONEXTON Gel (clindamycin phosphate and benzoyl peroxide), used as a once-daily treatment of comedonal and inflammatory acne.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com